Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MAGnetic hyperthermia agents based on Magnetically Activated microroBOTS.

Project description

Microrobots for magnetic hyperthermia cancer therapy

Magnetic hyperthermia is a minimally invasive treatment for cancer that uses magnetic nanoparticles to destroy tumour cells. Magnetic hyperthermia improves the efficacy of radiotherapy, chemotherapy and immune response in the destruction of tumour cells. Supported by the Marie Skłodowska-Curie Actions Programme, the MAGMAbots project aims to develop magnetically actuated microrobots (MAMs) through magnetic nanoparticles in neutrophils, probiotic bacteria and magnetotactic bacteria for magnetic hyperthermia cancer treatment and imaging diagnostics. The project will construct neu-MAGMAbot for assessment of the efficacy of treatments against glioblastoma, pro-MAGMAbot for targeting colon cancers and mag-MAGMAbot for improved diagnostic capabilities of magnetotactic bacteria. The project aims at providing innovations in non-invasive cancer treatment technologies in Europe.

Objective

The MAGMAbots project proposes the development of three innovative magnetically actuated microrobots (MAMs)—based on magnetic nanoparticles (MNP)-loaded neutrophils, probiotic bacteria, and magnetotactic bacteria—for cancer therapy through magnetic hyperthermia (MHT) and advanced imaging. The objectives are: (1) to design and characterize neu-MAGMAbot, an MAM based on neutrophils, evaluating its penetration across a 3D blood–brain barrier (BBB) model and its anticancer activity against glioblastoma; (2) to engineer pro-MAGMAbot, a probiotic-based microrobot, and test its targeting, cytotoxicity, and hyperthermia performance in colorectal cancer spheroids; and (3) to develop mag-MAGMAbot, MAMs based on magnetotactic bacteria with enhanced magnetosome-based magnetic and diagnostic properties.
The project will achieve these objectives based on a patented-driven methodology. This strategy preserves cell viability while enabling robust MNP internalization, and subsequent magnetic guidance via rotating magnetic fields, and real-time tracking through MPI/MRI. The work plan integrates advanced nanoparticle engineering, microfluidic BBB-on-chip models, 3D cancer spheroids, and multimodal imaging technologies, supported by the host group’s expertise in nanomaterials, magnetism, and biomedical applications.
Aligned with Horizon Europe’s Health Cluster and the Mission on Cancer, MAGMAbots directly addresses the challenge of developing innovative, non-invasive, and cost-effective therapeutic solutions for hard-to-treat tumours such as glioblastoma and colorectal cancer. Beyond the project’s duration, the results are expected to pave the way for scalable, patentable biohybrid microrobots, reduce healthcare costs, and reinforce European leadership in nanomedicine and biomedical innovation.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
Net EU contribution
€ 209 483,28
Address
VIA MOREGO 30
16163 Genova
Italy
Region
Nord-Ovest Liguria Genova
Activity type
Research Organisations
Links
Total cost
No data